Anti-Orexin Receptor 2 antibody

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

The Orexin Receptor 2 also known as Orexin 2 receptor or hypocretin receptor 2 is a G-protein coupled receptor (GPCR) encoded by the HCRTR2 gene. This receptor has a molecular weight of approximately 50 kDa. Expressed mainly in the brain including the hypothalamus hippocampus and certain cortical regions the receptor interacts with the neuropeptides orexin A and orexin B. The receptor activation triggers intracellular signaling cascades involving the Gq and Gi proteins which modulate neural activity.

Biological function summary

The Orexin Receptor 2 plays a critical role in maintaining wakefulness and energy metabolism. This receptor does not function as part of a larger protein complex but its interactions with the orexins influence diverse physiological responses like feeding behavior arousal and sleep-wake cycles. Orexin GPCRs including Orexin Receptor 2 have distinct but overlapping roles in these processes.

Pathways

Orexin Receptor 2 integrates into the neural circuits regulating the sleep-wake cycle and energy homeostasis. It participates in the orexin signaling pathway influencing neurotransmitter release that affects arousal and appetite. Additionally the receptor links with proteins such as orexin itself and other neurotransmitters which modulate sleep and arousal states through interconnected pathways including the limbic system.

Associated diseases and disorders

Orexin Receptor 2 is closely linked to conditions such as narcolepsy and insomnia. Narcolepsy characterized by excessive daytime sleepiness and sudden loss of muscle tone often involves disrupted orexin signaling due to low orexin levels or receptor dysfunction. Furthermore the receptor targets have been explored in the context of insomnia treatments focusing on their ability to regulate sleep patterns. Altered orexin signaling involving the Orexin 2 protein and other related neurotransmitters can impact both conditions showing the receptor’s clinical significance.